NCT04550104 2025-12-19
CONCORDE
University of Leeds
Phase 1 Recruiting
Clinical Trials
6 trialsNCT05568212 2025-12-01
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
Fondazione Ricerca Traslazionale
Phase 2 Recruiting
NCT06130254 2025-10-14
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05623319 2025-06-24
THOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT04515836 2025-05-06
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Phase 2 Recruiting
NCT06217757 2024-05-13
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting